Glucose Metabolism Reprogramming in Hematological Malignancies: Research Progress on Molecular Regulatory Networks and Clinical Translation
Cancer Management and Research · 2026-11 · Volume 18 · 1-14
DOI: 10.2147/cmar.s636252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Management and Research, 2026-11. Verfasst von Haijing Zhao und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Hematological malignancies, including leukemia, lymphoma, and multiple myeloma, are characterized by high heterogeneity and poor prognosis, with refractory relapse remaining a core clinical challenge. Glucose metabolism reprogramming is one of the core hallmarks of cancer cells. It not only provides energy and biomolecular building blocks for malignant cell proliferation but also extensively participates in stemness maintenance, immune evasion, and drug resistance development, thus becoming a critical target for the diagnosis and treatment of hematological tumors. In this review, we comprehensively reviewed the core biological features of glucose metabolism reprogramming in hematological malignancies, including activated aerobic glycolysis, enhanced metabolic plasticity, and prominent metabolic heterogeneity. We comprehensively dissect the multi-dimensional molecular regulatory network of glucose metabolism reprogramming from five levels: transcription factors and epigenetic regulation, oncogenes and signaling pathways, immune checkpoints and tumor microenvironment, post-translational modifications of metabolic enzymes, and post-transcriptional regulation by non-coding RNAs. Furthermore, we elaborate on the core pathogenic mechanisms by which abnormal glucose metabolism drives tumor initiation and progression, maintains leukemia stem cell stemness, and mediates chemotherapeutic and targeted drug resistance. On this basis, this paper summarizes the current clinical application status of glucose metabolism-related biomarkers in diagnosis, prognosis, and therapeutic efficacy monitoring, and concludes translational therapeutic strategies such as targeting key metabolic enzymes, upstream regulatory pathways, multi-drug combination therapy, and repurposing of hypoglycemic drugs.
Zitieren
APA
Zhao, H., Zhao, Z., & Zhang, J. (2026). Glucose Metabolism Reprogramming in Hematological Malignancies: Research Progress on Molecular Regulatory Networks and Clinical Translation. Cancer Management and Research, Volume 18, 1-14. https://doi.org/10.2147/cmar.s636252
Vancouver
Zhao H, Zhao Z, Zhang J. Glucose Metabolism Reprogramming in Hematological Malignancies: Research Progress on Molecular Regulatory Networks and Clinical Translation. Cancer Management and Research. 2026;Volume 18:1-14. doi:10.2147/cmar.s636252
BibTeX
@article{Zhao2026,
author = {Zhao, Haijing and Zhao, Zichun and Zhang, Jingqi},
title = {Glucose Metabolism Reprogramming in Hematological Malignancies: Research Progress on Molecular Regulatory Networks and Clinical Translation},
journal = {Cancer Management and Research},
year = {2026},
volume = {Volume 18},
pages = {1--14},
doi = {10.2147/cmar.s636252}
}
EUVIMED